822.51
price down icon0.27%   -2.25
after-market 시간 외 거래: 822.00 -0.51 -0.06%
loading
전일 마감가:
$824.76
열려 있는:
$833.42
하루 거래량:
2.27M
Relative Volume:
0.68
시가총액:
$738.75B
수익:
$45.04B
순이익/손실:
$10.59B
주가수익비율:
70.24
EPS:
11.71
순현금흐름:
$414.30M
1주 성능:
-0.19%
1개월 성능:
-4.05%
6개월 성능:
-9.11%
1년 성능:
+7.85%
1일 변동 폭
Value
$812.62
$836.29
1주일 범위
Value
$795.38
$836.29
52주 변동 폭
Value
$711.40
$972.53

일라이 릴리 Stock (LLY) Company Profile

Name
명칭
Lilly Eli Co
Name
전화
(317) 276-2000
Name
주소
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Name
직원
47,000
Name
트위터
@LillyPad
Name
다음 수익 날짜
2024-10-30
Name
최신 SEC 제출 서류
Name
LLY's Discussions on Twitter

LLY을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Drug Manufacturers - General icon
LLY
Lilly Eli Co
822.51 738.75B 45.04B 10.59B 414.30M 11.71
Drug Manufacturers - General icon
ABBV
Abbvie Inc
213.85 377.52B 56.33B 4.28B 17.83B 2.40
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
80.98 359.47B 42.09B 14.65B 10.11B 3.2833
Drug Manufacturers - General icon
JNJ
Johnson Johnson
164.25 344.63B 88.82B 14.07B 18.06B 5.79
Drug Manufacturers - General icon
MRK
Merck Co Inc
94.72 251.88B 64.17B 17.12B 18.10B 6.73

일라이 릴리 Stock (LLY) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2024-12-10 재개 BofA Securities Buy
2024-11-15 개시 Wolfe Research Outperform
2024-10-17 개시 Bernstein Outperform
2024-09-13 재개 Citigroup Buy
2024-08-12 업그레이드 Deutsche Bank Hold → Buy
2024-02-21 다운그레이드 DZ Bank Buy → Hold
2024-02-16 재확인 Morgan Stanley Overweight
2023-12-21 다운그레이드 Daiwa Securities Buy → Outperform
2023-11-09 개시 Deutsche Bank Hold
2023-10-20 재개 UBS Buy
2023-08-09 업그레이드 Jefferies Hold → Buy
2023-07-26 재확인 Citigroup Buy
2023-07-14 개시 HSBC Securities Buy
2023-05-24 재확인 BofA Securities Buy
2023-05-24 재확인 UBS Buy
2023-03-13 업그레이드 Wells Fargo Equal Weight → Overweight
2023-03-06 개시 Jefferies Hold
2023-02-15 다운그레이드 Societe Generale Hold → Sell
2022-11-18 개시 Credit Suisse Outperform
2022-09-22 업그레이드 UBS Neutral → Buy
2022-05-23 개시 SVB Leerink Outperform
2022-04-06 재개 Morgan Stanley Overweight
2022-03-10 개시 Daiwa Securities Outperform
2022-01-21 업그레이드 DZ Bank Hold → Buy
2022-01-03 재확인 Bernstein Mkt Perform
2021-12-17 개시 Goldman Neutral
2021-12-16 재확인 BMO Capital Markets Outperform
2021-12-16 재확인 BofA Securities Buy
2021-12-09 재개 Wells Fargo Equal Weight
2021-11-19 개시 BMO Capital Markets Outperform
2021-10-11 업그레이드 Berenberg Hold → Buy
2021-09-29 업그레이드 Citigroup Neutral → Buy
2021-08-05 업그레이드 DZ Bank Hold → Buy
2021-07-27 재개 Truist Buy
2021-06-24 재확인 Cantor Fitzgerald Overweight
2021-01-19 업그레이드 Mizuho Neutral → Buy
2020-12-10 업그레이드 Wolfe Research Peer Perform → Outperform
2020-11-10 재개 Bernstein Mkt Perform
2020-09-29 개시 Berenberg Hold
2020-09-03 업그레이드 Morgan Stanley Equal-Weight → Overweight
2020-06-16 업그레이드 Guggenheim Neutral → Buy
2020-04-21 다운그레이드 UBS Buy → Neutral
2020-04-09 다운그레이드 Morgan Stanley Overweight → Equal-Weight
2020-02-06 개시 Mizuho Neutral
2019-12-18 업그레이드 Morgan Stanley Equal-Weight → Overweight
2019-10-17 재개 BofA/Merrill Buy
2019-05-28 개시 Goldman Buy
2019-04-24 업그레이드 Edward Jones Hold → Buy
2019-04-11 다운그레이드 Guggenheim Buy → Neutral
2019-03-12 개시 JP Morgan Overweight
2019-01-23 개시 UBS Buy
2018-11-26 다운그레이드 Citigroup Buy → Neutral
2018-10-31 업그레이드 Credit Suisse Underperform → Neutral
2018-10-09 개시 Guggenheim Buy
2018-10-01 재확인 SunTrust Buy
2018-09-26 재개 JP Morgan Overweight
모두보기

일라이 릴리 주식(LLY)의 최신 뉴스

pulisher
05:09 AM

Eli Lilly And Company (LLY): Among Stocks to Buy That May Be Splitting Soon - Insider Monkey

05:09 AM
pulisher
01:43 AM

Is Eli Lilly and Company (LLY) the Best Diabetes Stock to Buy According to Billionaires? - Insider Monkey

01:43 AM
pulisher
01:15 AM

Eli Lilly’s $3B Expansion Gets Green Light in Kenosha County - Civic Media

01:15 AM
pulisher
08:56 AM

Eli Lilly stock holds strong on Outperform rating by Bernstein - Investing.com

08:56 AM
pulisher
08:53 AM

Jim Cramer Says Eli Lilly And Co (LLY) Sellers Are ‘Uninformed’ - Insider Monkey

08:53 AM
pulisher
Mar 17, 2025

Eli Lilly wins final approval for $3B expansion in Pleasant Prairie - The Business Journals

Mar 17, 2025
pulisher
Mar 17, 2025

Eli Lilly, Pfizer Back Teva Fight of US Drug Price Negotiations - Bloomberg Law

Mar 17, 2025
pulisher
Mar 17, 2025

Eli Lilly: A Safe Harbor Amid Market Volatility (NYSE:LLY) - Seeking Alpha

Mar 17, 2025
pulisher
Mar 17, 2025

Positive Outlook for Eli Lilly & Co. Amid FDA Support and Strong Revenue Projections - TipRanks

Mar 17, 2025
pulisher
Mar 17, 2025

Citi sees positive read-through to Lilly shares on FDA GLP-1 statement - TipRanks

Mar 17, 2025
pulisher
Mar 17, 2025

This Is What Whales Are Betting On Eli Lilly - Benzinga

Mar 17, 2025
pulisher
Mar 17, 2025

Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance

Mar 17, 2025
pulisher
Mar 17, 2025

3 Unstoppable Stocks You Can Buy Now Without Any Hesitation - The Motley Fool

Mar 17, 2025
pulisher
Mar 17, 2025

Pharmaceutical Giants Like J&J, Merck, and Eli Lilly Accelerate - openPR

Mar 17, 2025
pulisher
Mar 17, 2025

How Eli Lilly is Shaping Kinsale and Ireland's Economic LandscapeNews and Statistics - IndexBox, Inc.

Mar 17, 2025
pulisher
Mar 16, 2025

Is Eli Lilly and Company (LLY) the Best Quality Stock to Invest in Now? - MSN

Mar 16, 2025
pulisher
Mar 16, 2025

Jim Cramer Says: “Keep an Eye on Eli Lilly and Company (LLY)” - Insider Monkey

Mar 16, 2025
pulisher
Mar 16, 2025

Slow NHS puts investment at risk, warns ‘King Kong’ weight-loss jab maker - The Telegraph

Mar 16, 2025
pulisher
Mar 15, 2025

Tesla's problems, Eli Lilly's weight loss pill, and egg prices surge: Business news roundup - Yahoo Finance

Mar 15, 2025
pulisher
Mar 14, 2025

Eli Lilly snaps six days of losses - Seeking Alpha

Mar 14, 2025
pulisher
Mar 14, 2025

Eli Lilly Reverses Its Recent Run On Market Malaise. Is It A Sell? - Investor's Business Daily

Mar 14, 2025
pulisher
Mar 14, 2025

Senators expand probe of Pfizer, Lilly DTC platforms to include telehealth provider partners - FiercePharma

Mar 14, 2025
pulisher
Mar 14, 2025

Altimmune to study obesity drug in alcohol use disorder, following Eli Lilly - STAT

Mar 14, 2025
pulisher
Mar 13, 2025

Bioengineered Protein Drugs Market Size to Cross USD 672.7 Billion by 2034, Growing at a CAGR of 6.2% - GlobeNewswire Inc.

Mar 13, 2025
pulisher
Mar 13, 2025

AbbVie Is Preparing To Challenge Eli Lilly And Novo Nordisk (NYSE:ABBV) - Seeking Alpha

Mar 13, 2025
pulisher
Mar 13, 2025

Eli Lilly’s SVP Donald Zakrowski sells $818,240 in stock - Investing.com

Mar 13, 2025
pulisher
Mar 13, 2025

Eli Lilly’s Promising Position in Weight Management Market Drives Buy Rating - TipRanks

Mar 13, 2025
pulisher
Mar 12, 2025

Lilly, J&J boosted spending on executive security after UnitedHealth shooting - MSN

Mar 12, 2025
pulisher
Mar 12, 2025

Is Eli Lilly and Company (LLY) the Best Pharma Stock to Buy According to Hedge Funds? - Insider Monkey

Mar 12, 2025
pulisher
Mar 12, 2025

Telehealth platforms in senators’ crosshairs over relationship with Eli Lilly, Pfizer - STAT

Mar 12, 2025
pulisher
Mar 12, 2025

Durbin, Warren, Welch, Sanders Demand Answers From Telehealth Companies Regarding Their Financial Relationship With Pfizer, Eli Lilly Amid Concerns - RiverBender.com

Mar 12, 2025
pulisher
Mar 12, 2025

Roche Targets Weight-Loss Drug Market Dominated by Novo Nordisk, Eli Lilly - Investopedia

Mar 12, 2025
pulisher
Mar 12, 2025

Lilly CEO got a big payday (and an Olympics treat) - STAT

Mar 12, 2025
pulisher
Mar 11, 2025

Eli Lilly Suit Over Compounded Drugs Survives Dismissal - Law360

Mar 11, 2025
pulisher
Mar 11, 2025

Eli Lilly’s Dave Ricks takes home $114 million as obesity drugs fuel company’s fortunes - STAT

Mar 11, 2025
pulisher
Mar 11, 2025

Is Eli Lilly and Company (LLY) the Best Low Risk Stock to Buy In 2025? - Insider Monkey

Mar 11, 2025
pulisher
Mar 11, 2025

Eli Lilly-Incyte Partnered FDA-Approved Drug Shows Encouraging Efficacy In Adolescent Patients With Patchy Hair Loss - AOL

Mar 11, 2025
pulisher
Mar 11, 2025

Unpacking the Latest Options Trading Trends in Eli Lilly - Benzinga

Mar 11, 2025
pulisher
Mar 11, 2025

Eli Lilly & Co: Promising CagriSema Performance Justifies Buy Rating Despite Tolerability Concerns - TipRanks

Mar 11, 2025
pulisher
Mar 11, 2025

Eli Lilly Rises 7.5% YTD: Time to Buy, Sell or Hold the Stock? - Nasdaq

Mar 11, 2025
pulisher
Mar 11, 2025

Is Eli Lilly Stock a Buy? - The Motley Fool

Mar 11, 2025
pulisher
Mar 10, 2025

Why Eli Lilly Stock Flopped Today - The Motley Fool

Mar 10, 2025
pulisher
Mar 10, 2025

Novo Nordisk Dives 9%. Why Eli Lilly Now Has The Upper Hand. - Investor's Business Daily

Mar 10, 2025
pulisher
Mar 10, 2025

Eli Lilly's first weight loss pill could expand access to GLP-1s around the globe, executive says - Yahoo Finance

Mar 10, 2025
pulisher
Mar 10, 2025

Lilly sees launching weight loss drugs in China, India starting late 2025 - Seeking Alpha

Mar 10, 2025
pulisher
Mar 10, 2025

Judge Denies Injunction for Copycats of Lilly's Weight Loss Drug - Bloomberg Law

Mar 10, 2025
pulisher
Mar 10, 2025

Eli Lilly plans to launch weight-loss drug in emerging markets this year - Reuters

Mar 10, 2025
pulisher
Mar 10, 2025

Eli Lilly to debut weight loss drug in China, India - baha news

Mar 10, 2025
pulisher
Mar 10, 2025

Eli Lilly plans launch of weight-loss drug in emerging markets in 2025, CFO says - Bilyonaryo Business News

Mar 10, 2025
pulisher
Mar 10, 2025

Morgan Stanley maintains Eli Lilly Overweight rating, $1,146 target By Investing.com - Investing.com South Africa

Mar 10, 2025
pulisher
Mar 10, 2025

Eli Lilly plans to launch Mounjaro in China, India, Brazil and Mexico by 2026, CFO says - Marketscreener.com

Mar 10, 2025

일라이 릴리 (LLY) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$213.85
price down icon 0.29%
drug_manufacturers_general NVO
$80.98
price up icon 1.04%
drug_manufacturers_general JNJ
$164.25
price up icon 0.87%
drug_manufacturers_general MRK
$94.72
price down icon 0.07%
drug_manufacturers_general NVS
$112.22
price up icon 0.00%
자본화:     |  볼륨(24시간):